Published in J Biol Chem on December 21, 2011
Retracted The effect of soluble RAGE on inhibition of angiotensin II-mediated atherosclerosis in apolipoprotein E deficient mice. PLoS One (2013) 1.47
The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene (2013) 1.43
Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab (2013) 1.30
The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol (2012) 1.12
Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways. Circ Res (2012) 0.96
Oligomerization interface of RAGE receptor revealed by MS-monitored hydrogen deuterium exchange. PLoS One (2013) 0.91
Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway. Cardiovasc Diabetol (2013) 0.91
Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. Clin Pharmacol Ther (2015) 0.85
The novel RAGE interactor PRAK is associated with autophagy signaling in Alzheimer's disease pathogenesis. Mol Neurodegener (2016) 0.85
Cellular mechanisms and consequences of glycation in atherosclerosis and obesity. Biochim Biophys Acta (2016) 0.83
Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function. PLoS One (2013) 0.81
Identifying key juxtamembrane interactions in cell membranes using AraC-based transcriptional reporter assay (AraTM). J Biol Chem (2012) 0.81
Modeling the interaction between quinolinate and the receptor for advanced glycation end products (RAGE): relevance for early neuropathological processes. PLoS One (2015) 0.79
Increased expression of the receptor for advanced glycation end-products in human peripheral neuropathies. Brain Behav (2013) 0.79
The multiple faces of RAGE - opportunities for therapeutic intervention in aging and chronic disease. Expert Opin Ther Targets (2015) 0.78
Structural insights into the binding of the human receptor for advanced glycation end products (RAGE) by S100B, as revealed by an S100B-RAGE-derived peptide complex. Acta Crystallogr D Biol Crystallogr (2015) 0.77
Ischemia-reperfusion injury of the retina is linked to necroptosis via the ERK1/2-RIP3 pathway. Mol Vis (2014) 0.77
NMR characterization of the C-terminal tail of full-length RAGE in a membrane mimicking environment. J Biomol NMR (2012) 0.77
Glycation & the RAGE axis: targeting signal transduction through Diaph1. Expert Rev Proteomics (2016) 0.76
Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction. Sci Rep (2016) 0.76
Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling. Structure (2016) 0.76
2016 ATVB Plenary Lecture: Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis an Treatment of Cardiometabolic Disorders: Spotlight on the Macrophage. Arterioscler Thromb Vasc Biol (2017) 0.75
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem (2017) 0.75
AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR (1996) 29.55
Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J Biomol NMR (1999) 26.99
Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation. Biochemistry (1994) 13.94
Primary structure effects on peptide group hydrogen exchange. Proteins (1993) 10.79
Automated NMR structure calculation with CYANA. Methods Mol Biol (2004) 9.31
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60
p140mDia, a mammalian homolog of Drosophila diaphanous, is a target protein for Rho small GTPase and is a ligand for profilin. EMBO J (1997) 5.03
Formin proteins: a domain-based approach. Trends Biochem Sci (2005) 3.45
Structural basis of actin filament nucleation and processive capping by a formin homology 2 domain. Nature (2005) 3.31
Mapping protein-protein interactions in solution by NMR spectroscopy. Biochemistry (2002) 3.31
The formins: active scaffolds that remodel the cytoskeleton. Trends Cell Biol (2003) 3.13
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
Identification of a carboxyl-terminal diaphanous-related formin homology protein autoregulatory domain. J Biol Chem (2000) 2.86
Actin polymerization-driven molecular movement of mDia1 in living cells. Science (2004) 2.80
Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res (1999) 2.59
Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem (1997) 2.53
Structural and mechanistic insights into the interaction between Rho and mammalian Dia. Nature (2005) 2.52
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Structure of the autoinhibitory switch in formin mDia1. Structure (2006) 2.26
The regulation of mDia1 by autoinhibition and its release by Rho*GTP. EMBO J (2005) 2.10
Response to injury and atherogenesis. Am J Pathol (1977) 2.09
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
Identification, classification, and expression of RAGE gene splice variants. FASEB J (2007) 1.96
The main-chain dynamics of the dynamin pleckstrin homology (PH) domain in solution: analysis of 15N relaxation with monomer/dimer equilibration. J Mol Biol (1997) 1.95
Magnetically orientable phospholipid bilayers containing small amounts of a bile salt analogue, CHAPSO. Biophys J (1990) 1.95
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
The core FH2 domain of diaphanous-related formins is an elongated actin binding protein that inhibits polymerization. Mol Cell (2004) 1.74
Structural and functional insights into RAGE activation by multimeric S100B. EMBO J (2007) 1.59
The CCPN project: an interim report on a data model for the NMR community. Nat Struct Biol (2002) 1.58
Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem (2008) 1.51
The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry (2007) 1.51
Structural basis for ligand recognition and activation of RAGE. Structure (2010) 1.50
Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem (2006) 1.40
Formation of a native-like subdomain in a partially folded intermediate of bovine pancreatic trypsin inhibitor. Protein Sci (1994) 1.35
RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J (2004) 1.35
AutoLink: automated sequential resonance assignment of biopolymers from NMR data by relative-hypothesis-prioritization-based simulated logic. J Magn Reson (2005) 1.28
Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep (2011) 1.28
Amide proton exchange in proteins by EX1 kinetics: studies of the basic pancreatic trypsin inhibitor at variable p2H and temperature. Biochemistry (1985) 1.28
MBP fusion protein with a viral protease cleavage site: one-step cleavage/purification of insoluble proteins. Biotechniques (2001) 1.25
Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem (2010) 1.19
Selective inhibition of retinal angiogenesis by targeting PI3 kinase. PLoS One (2009) 1.04
A billion-fold range in acidity for the solvent-exposed amides of Pyrococcus furiosus rubredoxin. Biochemistry (2008) 0.99
Discovering protein secondary structures: classification and description of isolated alpha-turns. Biopolymers (1996) 0.96
Crystal structure of the Formin mDia1 in autoinhibited conformation. PLoS One (2010) 0.96
Intramolecularly hydrogen-bonded peptide conformations. CRC Crit Rev Biochem (1980) 0.94
NMR-detected order in core residues of denatured bovine pancreatic trypsin inhibitor. Biochemistry (2001) 0.88
The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol Dial Transplant (1996) 0.87
Structure of cyclic peptides: the crystal and solution conformation of cyclo(Phe-Phe-Aib-Leu-Pro). J Pept Res (1998) 0.77
Structure-toxicity relationships in the amatoxin series. Structural variations of side chain 3 and inhibition of RNA polymerase II. Int J Pept Protein Res (1992) 0.77
Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation (2006) 5.31
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res (2004) 4.00
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation (2002) 3.93
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology (2005) 2.74
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res (2003) 2.25
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res (2010) 2.19
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2003) 2.17
Mapping structural interactions using in-cell NMR spectroscopy (STINT-NMR). Nat Methods (2006) 2.15
The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation (2003) 2.14
Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab (2008) 2.13
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem (2003) 2.05
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
Identification, classification, and expression of RAGE gene splice variants. FASEB J (2007) 1.96
Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res (2008) 1.94
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts. J Leukoc Biol (2009) 1.84
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology (2004) 1.77
Protein glycation: a firm link to endothelial cell dysfunction. Circ Res (2004) 1.76
RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis (2005) 1.67
Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci (2008) 1.67
Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med (2003) 1.62
Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci (2011) 1.60
Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg (2009) 1.60
Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J (2013) 1.60
Development of receptor for advanced glycation end products-directed imaging of atherosclerotic plaque in a murine model of spontaneous atherosclerosis. Circ Cardiovasc Imaging (2008) 1.58
Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev (2002) 1.56
The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.55
Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol (2004) 1.55
PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice. Arterioscler Thromb Vasc Biol (2013) 1.52
RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) (2009) 1.52
Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem (2008) 1.51
Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) (2009) 1.51
Semisynthesis of a segmental isotopically labeled protein splicing precursor: NMR evidence for an unusual peptide bond at the N-extein-intein junction. Proc Natl Acad Sci U S A (2004) 1.51
Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation (2006) 1.48
Retracted Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes (2007) 1.44
RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum (2007) 1.44
RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol (2008) 1.41
Imaging of receptors for advanced glycation end products in experimental myocardial ischemia and reperfusion injury. JACC Cardiovasc Imaging (2012) 1.40
Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem (2006) 1.40
Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol (2005) 1.39
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J (2009) 1.39
RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med (2007) 1.38
Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation (2003) 1.38
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol (2006) 1.38
Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev (2002) 1.37
Autoregulation of a bacterial sigma factor explored by using segmental isotopic labeling and NMR. Proc Natl Acad Sci U S A (2002) 1.36
Bicoid cooperative DNA binding is critical for embryonic patterning in Drosophila. Proc Natl Acad Sci U S A (2005) 1.36
Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol (2007) 1.36
Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Mol Nutr Food Res (2007) 1.35
RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J (2004) 1.35
RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med (2005) 1.35
The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med (2009) 1.35
AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol (2008) 1.32
Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes (2010) 1.32
Mechanisms for the induction of HNE- MDA- and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp Eye Res (2005) 1.31
Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep (2002) 1.30
Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol (2003) 1.30
RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am J Physiol Heart Circ Physiol (2008) 1.29
At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol (2005) 1.27
Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation. Circ Res (2003) 1.27
Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J Immunol (2007) 1.26
Biosynthesis of a fully functional cyclotide inside living bacterial cells. Chembiochem (2007) 1.25
RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol (2002) 1.25
Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med (2009) 1.25
Biosynthesis and biological screening of a genetically encoded library based on the cyclotide MCoTI-I. Chembiochem (2009) 1.24
RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol (2008) 1.24